Yesterday, the Dow Jones Industrial Average
Today's quarterly report from Pfizer will give investors a peek at how major shifts within the company have been doing. While losing its Lipitor patent helped to cut net income in half last quarter, the company aims to cut $4 billion in expenses through 2012 and just sold its nutrition division to Nestle for more than $11 billion. Pfizer also looks forward to revenue from new drugs, including the FDA-approved Inlyta, developed to treat kidney cancer, and two drugs currently under review -- Eliquis, developed to help treat complications from irregular heartbeats, and bosutinib, developed to help treat leukemia.
Representing about 25% of total retail sales, car and truck sales can be a good indicator of total consumer demand. Forecasters estimate an increase in sales of 2% over last year, with GM
Further in the week
Kraft reports earnings on Thursday, and investors will also be watching the employment report released on Friday. While new jobless claims have been higher than analysts have expected, the market expects the unemployment rate to remain at 8.2%.
Every bit of news might nudge the stocks up or down for one day, but that doesn't mean much for long-term investors looking to outperform the market. A solid company pays no attention to the everyday changes in share price but instead looks for long-term value creation. To reveal three such solid stocks that will help you construct your retirement portfolio, along with the habits needed to build wealth far into the future, read our free report: "3 Stocks That Will Help You Retire Rich." It's free!
Motley Fool newsletter services have recommended buying shares of General Motors and Pfizer. The Motley Fool has a disclosure policy. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
Does a Strong Start Make 2018 a Sure Winner for Stocks?
Find out whether the so-called "January effect" is real.
Meet the 2018 Dogs of the Dow
Learn the basics of this simple dividend-investing strategy.
The Dow's Worst Day in 2017
Even with big gains, there were some scary times for the average.